Atkinson V., Ascierto P. A., Long G. V., Brady B., Dutriaux C., Maio M., Mortier L., Hassel J. C., Rutkowski P., McNeil C., Kalinka-Warzocha E., Lebbe C., Ny L., Chacon M., Queirolo P., Loquai C., Cheema P., Berrocal A., Eizmendi K. M., De la Cruz-Merino L., Bar-Sela G., Horak C., Jiang J., Hardy H., Robert C.
Two-year survival and safety update in patients (pts) with treatment-naive advanced melanoma (MEL) receiving nivolumab (NIVO) or dacarbazine (DTIC) in CheckMate 066.
J. Transl. Med..
2016
;14
Allayous C., Dalle S., Lacour J. P., Mortier L., Dutriaux C., Saiag P., Dalac S., Aubin F., Maubec E., Marie Beylot Barry, Lesimple T., Arnault J. P., De Quatrebarbes J., Stoebner P. E., Dreno B., Chami I., Porcher R., Kowal A., Leccia M. T., Lebbe C.
Immunotherapy-treated melanoma brain metastases within the French national cohort. MelBase.
J. Clin. Oncol..
2016
;34
:9556-9556